- Home
- Products
Libtayo (Cemiplimab-rwlc)
Libtayo (Cemiplimab-rwlc)
- Medicine Name: Libtayo
- Generic Name: Cemiplimab-rwlc
- Dosage Form & Strength: Injection – 350 mg/7 mL (50 mg/mL) solution in a single-dose vial
- Manufactured By: Sanofi
Libtayo (Cemiplimab-rwlc) is a PD-1 (programmed death receptor-1) blocking antibody approved for the treatment of:
- Cutaneous Squamous Cell Carcinoma (CSCC): For patients with metastatic or locally advanced CSCC not eligible for curative surgery or radiation
- Basal Cell Carcinoma (BCC): For locally advanced or metastatic BCC previously treated with or inappropriate for hedgehog pathway inhibitors
- Non-Small Cell Lung Cancer (NSCLC): As first-line treatment for locally advanced NSCLC with high PD-L1 expression, without EGFR, ALK, or ROS1 mutations
Recommended Dosage:
- 350 mg administered via IV infusion over 30 minutes every 3 weeks
- Continue until disease progression or unacceptable toxicity
Adrenal Insufficiency: Monitor for signs. Initiate hormone replacement therapy as needed
Hypophysitis: Can present with visual changes, photophobia, or headache. Requires prompt hormone replacement and monitoring
Thyroid Disorders: May include thyroiditis, hypothyroidism, or hyperthyroidism. Manage with hormone replacement as needed
Diabetes Mellitus: Monitor blood sugar; treat with insulin when necessary
Infusion-Related Reactions: May include severe reactions. Slow or interrupt infusion, or discontinue based on severity
HSCT Risks: Severe complications may occur if given prior to or after stem cell transplant
Fetal Toxicity: May harm the unborn child. Recommend contraception during treatment and for at least 4 months after the last dose
Documents Required to Import Libtayo to India:
- Valid prescription from a licensed doctor
- Diagnostic reports
- Government-issued photo ID
Order Confirmation:
- Confirmed upon receipt of all required documents and import permit (if needed)
Availability: Libtayo is available through Global Rare Meds across major Indian cities including Mumbai, Pune, Delhi, Chennai, Hyderabad, Bangalore, Ahmedabad, Kolkata, and others. Also available for eligible patients in SAARC and Gulf countries.
To Order or Enquire Price:
- Phone/WhatsApp: +91-99675 15602
- Email: info@globalraremeds.com
Global Rare Meds sources Libtayo from authorized suppliers in the USA, Europe, Canada, and Australia. All prescriptions are validated by licensed pharmacists and dispatched from our fulfillment center in Ambernath, Thane District.
We ensure compliance, safety, and fast delivery worldwide.
What is the generic name of Libtayo®?
Cemiplimab-rwlc
Who manufactures Libtayo®?
Sanofi
Is Libtayo® FDA approved?
Yes. Approved on September 28, 2018
What is the dosage form of Libtayo®?
Injection: 350 mg/7 mL (50 mg/mL) single-dose vial for IV use
What are the most common side effects?
Rash, musculoskeletal pain, fatigue, diarrhea
How much does Libtayo® cost in India?
Prices vary. Contact us at info@globalraremeds.com or WhatsApp +91-99675 15602 for the latest pricing
Can I buy Libtayo® online in India?
Yes, legally through Global Rare Meds under the Named Patient Program
How should Libtayo® be stored?
Refrigerate at 2°C to 8°C (36°F to 46°F). Protect from light. Do not freeze or shake
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
